Phase 2 Data Highlight the Observed Abscopal-like Effect of VP-315 in Non-treated Basal Cell Carcinoma Tumors WEST CHESTER, Pa., May 05, 2026 ...

June 15, 2012 — Vismodegib (Erivedge) "is the greatest advance in therapy yet" for the treatment of basal cell carcinoma (BCC), according to an editorial published in the June 7 issue of the New ...

Basal cell carcinoma (BCC) represents the most prevalent form of skin cancer, with research efforts increasingly focused on elucidating its molecular underpinnings and improving therapeutic strategies ...

A new study led by researchers at the Johns Hopkins Kimmel Cancer Center found that patients with advanced basal cell carcinoma (BCC) may benefit from receiving immunotherapy earlier in the course of ...

Medicus Pharma Ltd. MDCX on Wednesday reported expanded Phase 2 SKNJCT-003 study data showing a clear dose-response ...

Medicus Pharma Ltd. announced promising interim results from its SKNJCT-003 Phase 2 clinical study aimed at the non-invasive treatment of basal cell carcinoma (BCC) using the investigational product D ...

Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications ...

Add Yahoo as a preferred source to see more of our stories on Google. Skin cancer is the most common type of cancer in the United States with 5.4 million new cases of the disease reported every year.

Kevin Jonas, Christie Brinkley, Andy Cohen, Gordon Ramsay and more stars have opened up about skin cancer and the importance ...

Detailed price information for Verrica Pharmaceuticals Inc (VRCA-Q) from The Globe and Mail including charting and trades.